Who
Diane Jorkasky
Director
Company insider
Files Form 4 as: Director, Altimmune; Director, Q Therapeutics; Director, Tengion.
In numbers
- Trades disclosed
- 17
- Buys
- 1
- Sells
- 1
- Bought
- $2,003
- Sold
- $207K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 10 Aug 2011
- Last trade
- 1 May 2026
- Last filed
- 1 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 29 Dec 2025filed 29 Dec 2025 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $2,003527 at $3.80 | filing |
| 25 Sep 2025filed 29 Sep 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 26 Sep 2024filed 30 Sep 2024 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,900 at $0.00 | filing |
| 28 Sep 2023filed 29 Sep 2023 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,100 at $0.00 | filing |
| 29 Sep 2022filed 30 Sep 2022 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 27 Jun 2022filed 28 Jun 2022 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,610 at $0.00 | filing |
| 27 Jun 2022filed 28 Jun 2022 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $55K17,610 at $3.15 | filing |
| 27 Jun 2022filed 28 Jun 2022 | ALT AltimmuneBiotechnology | SEC FORM 4 Sold | $207K17,610 at $11.75 | filing |
| 23 Sep 2021filed 1 Oct 2021 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,100 at $0.00 | filing |
| 24 Sep 2020filed 28 Sep 2020 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 at $0.00 | filing |
| 11 May 2020filed 12 May 2020 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 18 Dec 2014filed 22 Dec 2014 | Q Therapeuticsoption or derivative | SEC FORM 4 Code A | $35K50,000 at $0.70 | filing |
| 21 May 2012filed 22 May 2012 | Tengionoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 Sep 2011filed 29 Sep 2011 | Tengionoption or derivative | SEC FORM 4 Code A | —4,700 at $0.00 | filing |
| 10 Aug 2011filed 12 Aug 2011 | Tengionoption or derivative | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Diane Jorkasky; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.